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5 
SCIENTIFIC JUDGMENT AND TOXIC 
TORTS—A PRIMER IN TOXICOLOGY FOR 
JUDGES AND LAWYERS 
David L. Eaton, Ph.D., DABT, FATS* 
I. GENES, ENVIRONMENT AND DISEASE 
Remarkable progress has been made in the past decade in 
understanding the molecular basis of many chronic diseases such 
as cancer, degenerative neurological diseases (Alzheimer’s, 
Parkinson’s), heart disease, and asthma. Although the molecular 
basis for such diseases has become more apparent, the exact 
“cause” is seldom identified for a disease in general, and especially 
for a disease in an individual. It is now recognized, however, that 
most such chronic diseases result from a complex interplay 
between our genes and our environment. While our parents 
predetermine our genes, our environment is somewhat 
controllable, and thus identifying “environmental risk factors” for 
chronic diseases holds great promise for disease prevention. It 
should be noted that “environment” in this context represents 
virtually everything in the world around us that is not “in our 
genes.” Thus environmental factors include lifestyle choices such 
as smoking, drug use and alcohol consumption, exposure to 
infectious agents (viruses, bacteria), as well as diet and nutrition, 
environmental pollution (air, water), and even behavioral and 
social factors such as exercise, reproductive choices, sexual 
activity, etc. 
There is currently great scientific effort committed to 
                                                          
 * Professor of Environmental and Occupational Health Sciences; Associate 
Dean for Research School of Public Health and Community Medicine at the 
University of Washington. 
EATON.DOC 2/23/2004  7:22 PM 
6 JOURNAL OF LAW AND POLICY 
identifying specific genetic characteristics (so-called “genetic 
polymorphisms”) that make one individual more susceptible to 
something in the environment than another.1 This area of research 
is sometimes referred to as “ecogenetics,” or the study of “gene-
environment interactions.”2 There are many classic examples of 
genetic characteristics that make an individual sensitive to 
something in his environment.  For example, the rare genetic 
disease, phenylketonuria (PKU), makes individuals with this 
genetic trait very sensitive to a normal component of our diet—
phenylalanine.  Phenylalanine is a normal building block of 
proteins, and in most people is an important nutrient in the diet. 
For a small part of the population with a mutation in the PKU 
gene, however, regular “doses” of phenylalanine found in the 
normal diet can lead to serious mental retardation if infants are 
exposed to phenylalanine. Because of this, genetic testing for PKU 
is mandatory in most states in the United States and is part of 
normal newborn screening. Those rare individuals who test 
positive for PKU can lead normal lives by following special diets 
and avoiding foods rich in phenylalanine. 
Another common example of a “gene-environment” interaction 
occurs in many people of Asian descent who carry a genetic 
variant of a gene involved in alcohol metabolism. Normally, 
alcohol is fairly rapidly detoxified in the liver. But individuals with 
a variant form of the gene for an enzyme called “aldehyde 
dehydrogenase” (ALDH2) are less able to eliminate a toxic by-
product of alcohol metabolism, acetaldehyde. If a person with the 
variant ALDH2 gene consumes even modest amounts of alcohol, 
toxic amounts of acetaldehyde can accumulate in the blood, 
causing a very uncomfortable reaction (“flushing” of the skin from 
vasodilatation, nausea, headache). Not surprisingly, alcoholism and 
alcohol-related diseases such as cirrhosis of the liver occur very 
                                                          
1 See Samir N. Kelada, David L. Eaton, Sophia S. Wang, Nathaniel R. 
Rothman & Mhuin J. Khoury, The Role of Genetic Polymorphisms in 
Environmental Health, 111 ENVTL. HEALTH PERSP. 1055-64 (2003). 
2 Gilbert S. Omenn, Public Health Genetics: An Emerging Interdisciplinary 
Field for the Post-Genomic Era, 21 ANN. REV. OF PUB. HEALTH 1, 1-13 (2000); 
Daniel W. Nebert & Michael J. Carvan, III, Ecogenetics: From Ecology to 
Health, 13 TOXICOLOGY AND INDUSTRIAL HEALTH 163, 163-92 (1997). 
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infrequently in people with this genetic trait. 
There is currently a great deal of interest in identifying 
common genetic traits that might combine with factors in our 
environment to cause disease. It is hoped that, one day, physicians 
will be able to characterize, or “genotype,” the entire genetic code 
of a person, and based on the results (kept on a personal microchip 
medical card), identify whether the patient is at increased risk for 
certain diseases and potentially identify specific dietary, 
workplace, or other environmental factors that should be avoided 
to lower risk. While we are still a decade or more away from 
having scientifically validated tests for “environmental 
susceptibility” to most environmental/occupational hazards, similar 
approaches for identifying how individuals respond to therapeutic 
drugs is just around the corner (the field of “Pharmacogenomics”). 
Indeed, there are now several relatively widespread genetic tests 
that can identify in advance patients who are likely to have adverse 
reactions to otherwise “normal” therapeutic doses of specific 
drugs.3 The concept of “designer drugs” is becoming a reality, but 
so far in a limited way. For example, there is a common genetic 
variant in a gene called “N-acetyl transferase.”  This gene is 
involved in the detoxification of a variety of therapeutic drugs, and 
people with the “slow” genetic variant exhibit increased toxicity 
(but also enhanced therapeutic effects at lower doses) to a variety 
of common drugs. Knowing this predisposition in advance allows 
physicians to prescribe the proper dose. 
How will such genetic information be used in the courtroom? 
In the realm of genetic testing for drug sensitivity, there will be 
medical malpractice claims filed against physicians who fail to 
order genetic tests before prescribing certain drugs, once such 
procedures become the standard of care.4 Drug companies will 
                                                          
3 Rafael Valdes Jr., Mark W. Linder & Saeed A. Jortani, What Is Next in 
Pharmacogenomics? Translating It to Clinical Practice, 4 
PHARMACOGENOMICS 499, 499-505 (2003). 
4 Jan van Aken, Mechteld Schmedders, Gunter Feuerstein & Regine 
Kollek, Prospects and Limits of Pharmacogenetics: The Thiopurine Methyl 
Transferase (TPMT) Experience, 3 AM. J. OF PHARMACOGENOMICS 149, 149-55 
(2003); Mark A. Rothstein & Sharona  Hoffman, Genetic Testing, Genetic 
Medicine, and Managed Care, 34 WAKE FOREST L. REV. 849 (1999). 
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attempt to increase drug safety and limit liability by identifying in 
advance drugs that may elicit adverse responses in small segments 
of the population because of genetic sensitivity. In the 
environmental and occupational arena, employers might use 
genetic tests as a way of identifying and removing “sensitive” 
individuals from certain workplace exposures.5 While such 
practice might conceivably lower the occurrence of chemical-
induced occupational diseases, it is obviously also a means of 
employment discrimination. It is also likely that plaintiff and 
defense attorneys will utilize genetic susceptibility as an argument 
for, or against, causation in toxic tort cases. Currently, however, 
the scientific data supporting the use of genetic susceptibility 
information in toxic tort litigation is extremely limited.6 In the vast 
majority of circumstances, specific and measurable genetic 
“susceptibility markers” often do little more than shift a person 
“up” or “down” the dose-response curve. Such differences tend to 
be modest (less than a two-fold difference in susceptibility), and 
the impact of the genetic trait is often lost in the “noisy 
background” of poor exposure assessment.7 That is, if one can only 
“guess” the dose, duration, and frequency of exposure to a specific 
chemical within a factor of 5 or 10 (not uncommon in toxic tort 
cases), a genetic factor that theoretically doubles or halves the risk 
from a given dose will not be particularly informative against the 
high level of uncertainty of the actual “exposure.” Thus, although 
genetic information will increasingly find its way into toxic tort 
                                                          
5 Robert J. McCunney, Genetic Testing: Ethical Implications in the 
Workplace, 17 OCCUPATIONAL MED.  665, 665-72 (2002); Steve M. Bartell, 
Raphael A. Ponce, Tim K. Takaro, Richard O. Zerbe, Gilbert S. Omenn & 
Elaine M. Faustman, Risk Estimation and Value-of Information Analysis for 
Three Proposed Genetic Screening Programs for Chronic Beryllium Disease 
Prevention, 20 RISK ANALYSIS 87, 87-99 (2000). 
6 Gary E. Marchant, Toxicogenomics and Toxic Torts, 20 TRENDS IN 
BIOTECHNOLOGY 329, 329-32 (2002). 
7 Werner K. Lutz, Differences in Individual Susceptibility to Toxic Effects 
of Chemicals Determine the Dose-Response Relationship and Consequences of 
Setting Exposure Standards, 126 TOXICOLOGY LETTER 155, 155-58 (2002); 
Marilyn J. Aardema & James T. MacGregor, Toxicology and Genetic 
Toxicology in the New Era of “Toxicogenomics”: Impact of “-Omics” 
Technologis, 499 MUTATATION RES. 13, 13-25 (2002). 
EATON.DOC 2/23/2004  7:22 PM 
 TOXICOLOGY IN LITIGATION 9 
litigation, the fundamental concepts of toxicology and 
epidemiology continue to serve as the foundation for establishing 
causation in toxic tort claims.8 The following information is 
provided as a “primer” in basic toxicology, as it relates to toxic tort 
litigation.  For a more detailed discussion of considerations of how 
the science of toxicology and epidemiology should be used in the 
courtroom, the reader is referred to the Federal Judicial Center’s 
Reference Manual on Scientific Evidence.9 This publication 
includes chapters devoted to toxicology and epidemiology, as well 
as medical testimony and use of DNA in the courtroom. 
II.  BASIC TOXICOLOGY RELEVANT TO TOXIC TORT LITIGATION 
Toxic substances may take many forms, including both human-
made (synthetic) and natural chemicals. Although the adverse 
effects of physical agents such as ionizing radiation fall under the 
broad rubric of toxicology, this discussion will focus on chemical 
agents. There are many “sub-disciplines” within the field of 
toxicology, and a variety of approaches and techniques are used to 
evaluate the toxicological characteristics of chemicals. A detailed 
review of the basic principles of toxicology is beyond the scope of 
this article.10 The following brief review highlights some of the 
key principles of toxicology that must be considered in any attempt 
to establish whether a chemical exposure was causally related to a 
specific adverse effect or disease in an individual. 
                                                          
8 Mark Parascandola & Douglas L. Weed, Causation in Epidemiology, 55 
J. EPIDEMIOLOGY COMMUNITY HEALTH 905, 905-12 (2001); see Marchant, 
supra note 6. 
9 FEDERAL JUDICIAL CENTER, REFERENCE MANUAL ON SCIENTIFIC 
EVIDENCE (2d ed. 2000). 
10 A number of fundamental textbooks are available that review the 
principles of toxicology in depth. See J. MARK ELWOOD, CAUSAL 
RELATIONSHIPS IN MEDICINE (1988); ALFRED S. EVANS, CAUSATION AND 
DISEASE (1993); KENNETH J. ROTHMAN, CAUSAL INFERENCE (1988); MERVYN 
W. SUSSER, CAUSAL THINKING IN THE HEALTH SCIENCES (1973). 
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A. Types of Adverse Effects Produced by Chemicals 
Virtually all substances are capable of inducing some form of 
toxic effect, and the type and nature of effects will vary depending 
on the 
• dose (amount of substance that finds its way into the body) 
• route (i.e., oral, inhalation, skin; injection) 
• duration (days, weeks, months, years) and 
• frequency (how many times per day, week, month, year) 
of exposure. 
A given chemical does not cause every possible effect, and the 
ability of a chemical to cause a particular effect depends upon a 
variety of factors, as discussed below. Typically, a specific 
chemical elicits a characteristic pattern of toxic (adverse) effects, 
although the appearance of specific effects will depend on the dose 
and other characteristics of exposure. Sometimes chemicals of a 
common type cause a generalized adverse response. For example, 
nearly all organic solvents derived from petroleum products 
(including mixtures such as gasoline or kerosene, or individual 
solvents such as benzene, hexane, or toluene) share some (but not 
all) symptoms in common: “defatting” of the skin following 
dermal exposure, and central nervous system depression 
(inebriation, loss of consciousness) following relatively high levels 
of inhalation exposure. However, even though different chemicals 
of the same general type (e.g., solvents) may have some common 
effects, they may also differ dramatically in other effects. For 
example, the industrial solvents benzene and toluene are very 
similar chemically, and share many common toxic effects noted 
above for solvents, but benzene is toxic to the bone marrow and 
can increase the risk of leukemia in workers, whereas these serious 
toxic effects have not been found for toluene. Thus, some 
chemicals act in very specific ways at the cellular level, and their 
effects may be largely limited to a characteristic type of response. 
As an example, the widely-used class of insecticides known as 
“organophosphates” inhibit a specific enzyme in the nervous 
system (acetylcholinesterase), and most of the signs and symptoms 
of toxicity can be attributed to this one mode of action. However, 
even small differences in chemical structure can sometimes make 
EATON.DOC 2/23/2004  7:22 PM 
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very large differences in the type of toxic response that is 
produced. This is especially true for chemicals that cause birth 
defects (teratogens) or chemicals that increase the risk of cancer 
(carcinogens). 
B.  Concepts of Dose and Exposure 
“Dose” refers to the amount of chemical that enters the body. 
The units of dose are typically expressed as an amount of 
substance per kg of body weight (mg/kg bw). Thus, if a 132 lb 
woman (60 kg) absorbed 60 milligrams of a chemical in a glass of 
contaminated water, she would have a dose of 1 mg/kg bw. Dose is 
the single most important factor to consider in evaluating whether 
an alleged exposure caused a specific adverse effect. Indeed, the 
basic dictum of toxicology was stated by the Sixteenth Century 
Physician/Philosopher, Paracelsus, considered the “father of 
toxicology”: “All substances are poisonous—there is none which is 
not; the dose differentiates a poison from a remedy.”11 
1. Relationship between “Exposure Concentration” and “Dose” 
Dose and “exposure” in terms of media (e.g., air, water, soil) 
concentration are related, but not identical, terms. Exposure may 
be referred to as the presence of a chemical in a medium (e.g., air, 
water, food) that allows for direct contact with potential sites of 
absorption (e.g., gastrointestinal tract, lungs, skin). The units of 
such exposure are usually expressed as concentrations—e.g., 
milligrams of chemical per liter of water (mg/L), milligrams of 
chemical per cubic meter of air (mg/m3), milligrams of chemical 
per kilogram of food (mg/kg). Frequently, such concentrations are 
expressed as “parts per million” (ppm) or “parts per billion” (ppb). 
For chemicals dissolved in water, 1 part per million is the same as 
1 milligram of chemical dissolved in 1 liter of water. One part per 
billion (1 ppb) is a thousand times less—1 milligram dissolved in a 
thousand liters of water, or 1 microgram of chemical dissolved in 1 
                                                          
11 CASARETT AND DOULL’S TOXICOLOGY: THE BASIC SCIENCE OF POISONS 
Chs. 1, 4 (Curtis D. Klaassen ed., McGraw Hill 6th ed. 2001) (emphasis added). 
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liter of water. A part per trillion (ppt), is 1,000 times less than a 
part per billion. To provide some perspective on these units, 
consider the following: 
• 1 ppm=1 penny in $10,000, or 1 inch in the distance of 15.8 
miles 
• 1 ppb=1 penny in $10 million, or 1 inch in 15,800 miles 
• 1 ppt=1 nickel of Bill Gates net worth (assuming $50 
billion), or 6 inches in the distance between the earth and 
the sun. 
Analytical tools developed in the past several decades make it 
possible to measure substances in water, food, soil or air at the ppt 
and even parts per quadrillion (ppqd; 1,000 times less than a ppt). 
It is evident from these simple analogies that, when discussing 
exposure to chemicals in drinking water, air, or soil, it is critically 
important that the relationship between exposure, as expressed as a 
concentration of a pollutant in a medium (measured in ppm, ppb, 
ppt or even ppqd) and the actual dose to a person not be lost. The 
science of toxicology can help understand whether the dose of a 
substance achieved following a particular exposure has any 
relationship to toxicity or disease. 
2. Frequency and Duration of Exposure 
Frequency and duration of exposure are important elements of 
“dose.”  Effects caused by chemicals may differ depending on 
whether exposure was short-term (e.g., acute, single dose or a few 
days) or long-term (chronic, repeated over years). The dose of a 
chemical required to produce health effects also differs with 
frequency and duration of exposure. When exposure occurs 
repeatedly over weeks, months, or years, the dose is usually 
expressed as a dose rate, with units of mg of chemical per kg of 
body weight per day. The dose necessary to produce deleterious 
effects with short-term exposure is higher than the dose that 
produces toxic effects when repeated over a long time period. The 
body can usually tolerate or recover from high doses with brief 
short-term exposure as compared to long-term repeated exposure. 
For example, one night of moderate drinking may give you no 
more than a headache the next day, but heavy drinking frequently 
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for years could lead to liver cirrhosis and possibly liver cancer. 
However, it is also possible that repeated, low dose exposures—
even for many years—will have no consequence at all, since the 
body is often able to completely detoxify low doses before they do 
any damage. This concept of “thresholds” will be discussed in 
more detail later. 
Most chemicals that have been identified to have “cancer-
causing” potential (carcinogens) do so only following long-term, 
repeated exposure for many years. Single exposures or even 
repeated exposures for relatively short periods of time (e.g., weeks 
or months) generally have little effect on the risk of cancer, unless 
the exposure was remarkably high and associated with other toxic 
effects. Relatively infrequent exposure may also have negligible 
health consequences even if continued over time because of 
recovery between doses. 
3. Pathways and Routes of Exposure 
“Pathways” are the means by which an environmental chemical 
may reach an “exposed” person. Chemicals can enter the body by 
four fundamental “routes”: (1) via oral exposure (e.g., ingestion of 
the toxic substance directly, or in food or drinking water), (2) via 
inhalation (e.g., breathing air or inhaling dust contaminated with 
the toxic substance), (3) via direct contact with the skin (e.g., 
spilling of a pesticide mixture on the skin), or (4) by direct 
injection into the body (e.g., introduction of a drug by intravenous 
injection). The “bioavailability”—or ability of the chemical to be 
taken into the blood stream—differs by route of entry. Most drugs 
and toxic chemicals will be well absorbed from the gut when 
ingested in a soluble form versus in other media such as soil. Many 
chemicals, however, are only slightly absorbed, if at all, if applied 
to the skin. However, fat-soluble chemicals in high concentration 
may be well absorbed across the skin, and this can lead to an 
important pathway of exposure for those using concentrated 
solutions in the workplace. The extent of inhalation absorption of 
chemical vapor will depend on a variety of factors, including the 
relative solubility of the chemical in blood versus air, the rate of 
breathing, and even whether one breathes through the nose or 
EATON.DOC 2/23/2004  7:22 PM 
14 JOURNAL OF LAW AND POLICY 
mouth. 
4. Site of Action in the Body 
Ultimately, what matters is the actual concentration of a toxic 
substance at the “site of action” in the body. The concentration of a 
chemical in any given organ/tissue in the body is determined by 
complex interactions between the rates of exposure, and rates of 
absorption, distribution, metabolism, and excretion. Because 
chemicals differ in their solubility in body fluids/tissues, in how 
they are metabolized, and in what cellular processes are altered, 
toxic effects of a chemical may be limited to specific tissues or 
organs, referred to as its “target tissue.” For example, lead and 
mercury typically produce toxic effects associated with the brain 
and kidneys, whereas certain chlorinated solvents such as 
chloroform and carbon tetrachloride affect predominantly the liver 
(although in high doses they also affect the brain). 
Many factors determine whether a chemical will be toxic to a 
particular organ. Some organs metabolize (biotransform) 
chemicals to toxic intermediates, leading to toxicity in that organ. 
In such instances, the relative ability of an organ or tissue to 
metabolize the chemical may determine whether the toxic effect is 
seen in that tissue. Certain tissues may also accumulate a chemical 
from the bloodstream at higher rates than other tissues, leading to 
toxicity in just that tissue. This is particularly true for tissue with a 
function (e.g., liver), but not necessarily for storage tissue, i.e., fat, 
which accumulates fat-soluble chemicals such as DDT, but is not 
directly injured. Metabolic pathways and the amount and type of 
toxic by-products produced or accumulated may also differ 
depending on the amount of chemical in the blood stream (which, 
of course, is directly related to dose). For example, metabolic 
pathways at low doses that result in chemical detoxification may 
be overwhelmed at high doses leading to accumulation of toxic 
intermediates or production of greater amounts of toxic by-
products by alternative pathways. 
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5. Dose-response Relationship 
As noted above, the relationship between dose and effect 
(dose-response relationship) is the hallmark of basic toxicology. 
The “dose-response” in a given individual describes the 
relationship between the magnitude or severity of the effect(s) and 
the dose. In many instances, especially for acute toxicity, the slope 
of the dose-response curve is quite steep. That is, once a sufficient 
dose has been achieved to induce a toxic response, further 
increases in the dose may produce large increases in the response. 
In the individual, the nature of the response may change with 
increasing dose. For example, ingestion of one or two glasses of 
wine will result in an apparent “stimulatory” effect on the nervous 
system, often expressed as slight changes in personality or 
character. Further consumption of alcohol will lead to loss of 
coordination and reaction time, slurred speech, etc. Continued 
consumption of alcohol beyond this level of intoxication may 
result in loss of consciousness and even death. 
Although individuals within a population may respond 
differently to the same dose of chemical, the reaction of the 
population as a whole nevertheless follows a “dose-response 
relationship” such that the number of people in a population that 
respond to a chemical exposure increases with dose. Inherent in 
this concept is that, for the vast majority of chemicals and types of 
responses, there are doses below which no individual will respond 
(e.g., a “threshold”) and doses above which nearly everyone 
responds. For example, no one would exhibit any detectable 
adverse effect of a few drops of wine or beer (e.g., the dose is 
below the threshold), yet most everyone in a population would 
show signs of intoxication after ingestion of an entire bottle of 
wine (over a relatively short period of time). In between these two 
extremes, there are clearly differences in the level of intoxication 
between individuals consuming one, two, three, or four glasses of 
wine. In a similar fashion, there is inherent human variability in 
response to chronic exposures to chemicals. Dose-response 
relationships in populations also exist for both acute and chronic 
exposures to toxic substances. 
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6. Concept of “Thresholds” 
For most types of dose-response relationships following 
chronic (repeated) exposure, thresholds exist, such that there is 
some dose below which even repeated, long term exposure would 
not cause an effect in any individual. Most toxicological responses, 
including neurological, reproductive, and developmental effects, 
exhibit thresholds (e.g., there is a dose below which the probability 
of an individual responding is essentially zero). One key objective 
in toxicology is to identify doses for a population below which no 
one will respond. However, in the case of chemical carcinogens, 
particularly those that increase risk of cancer by causing direct 
damage to DNA in cells, many regulatory agencies assume that 
there are no “thresholds,” and that risk is proportionate to dose at 
all levels of exposure—e.g., as the dose of carcinogen increases, 
the probability of developing cancer increases in a proportionate, 
“linear” fashion. 
Nonetheless, many scientific and practical reasons indicate 
that, at very low doses, the significance of such risks, if real, 
become trivial and are lost in the background of other daily risks. 
For example, it is well known that cigarette smoking is strongly 
associated with increased risk for lung and bladder cancer (and 
other types), and that the probability of developing such smoking-
related cancers is related to both the amount (cigarettes per day) 
and the frequency (years of smoking) of smoking over a life-
time.12 It is also recognized that the carcinogenic properties of 
cigarette smoke are strongly related to the ability of components of 
cigarette smoke to damage DNA (cause mutations), and thus it 
might be assumed that the dose-response relationship for smoking 
would be a “non-threshold” (linear at low doses) response.13 
However, while a linear, non-threshold response to cigarette smoke 
may be hypothesized on theoretical grounds, from a practical 
                                                          
12 See OFFICE OF THE SURGEON GENERAL, U.S. PUB. HEALTH SERV., DHHS 
PUB. NO. (CDC) 90-8416, THE HEALTH BENEFITS OF SMOKING CESSATION: A 
REPORT OF THE SURGEON GENERAL (1990). 
13 Ralph Zito, Low Doses and Thresholds in Genotoxicity: from Theories to 
Experiments, 20 J. EXPERIMENTAL CLINICAL CANCER RES. 315, 315-25 (2001). 
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perspective one’s level of increased risk from smoking one 
cigarette over a lifetime, or even one cigarette a month for a 
lifetime, is not likely to be distinguishable from “background” risk 
for cancer from all other causes, known and unknown. 
Not all chemical carcinogens increase cancer risk by causing 
mutation. For such “non-genotoxic” carcinogens, it is generally 
thought that the dose-response relationship follows a typical 
threshold-type response. Thus, it is often important to distinguish 
between “genotoxic” (particularly those that act directly on DNA 
to cause mutations) and “non-genotoxic” carcinogens for 
regulatory and risk assessment purposes. Practical thresholds may 
also exist for “genotoxic” carcinogens that damage DNA by 
indirect mechanisms (e.g., production of sufficient “reactive 
oxygen species” to cause oxidative damage, or sufficient inhibition 
of DNA repair mechanisms), because a sufficient amount of the 
chemical is needed before enough damage to the DNA occurs to 
lead to cancerous cells. 
C. Chemical Exposures and Chronic Diseases 
Traditional toxicology tests in laboratory animals are designed 
to identify toxic responses following various periods of exposure.14 
Acute toxicity studies examine the toxic effects after single, high 
doses and are useful to understand the specific organ systems 
affected by the chemical, as well as the general “potency” of its 
effect (e.g., does it require microgram, milligram, or gram 
quantities to produce evidence of toxicity?). Additional “sub-
chronic” (usually ninety days of daily exposure) and “chronic” 
(usually lifetime, or two years of continuous daily exposure) 
studies are often done to further examine whether the chemical is 
capable of causing other types of toxic effects following repeated 
exposures. Such studies may demonstrate that repeated exposure to 
a chemical could cause liver or kidney or brain damage, for 
example. Special “3-generation” studies may be done in animals to 
determine if the chemical can cause reproductive effects and/or 
                                                          
14 CASARETT AND DOULL’S TOXICOLOGY: THE BASIC SCIENCE OF POISONS, 
supra note 11, at chs. 2, 11-34. 
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birth defects. Today, new chemicals entering commerce, such as a 
new pesticide, may be subjected to specialized tests to determine if 
it can cause neurological effects on learning and behavior, or cause 
toxicity to the immune system. Each of these toxicological end-
points can be the subject of toxic tort litigation. However, 
regardless of the end-point, the basic concept of “dose-response” 
remains essential in evaluating a causal connection between an 
alleged exposure and a particular disease. As noted above, for non-
cancer end points, it is generally accepted that “thresholds” exist, 
and that doses below the threshold represent no risk. However, 
determining the “true” threshold for humans is difficult, if not 
impossible, and requires consideration of human variability. Thus, 
regulatory agencies often determine “safe” levels of exposure for 
non-cancer endpoints by dividing the highest dose that does not 
cause any evidence of toxicity upon repeated exposure to a group 
of laboratory animals (the so-called “No Observable Adverse 
Effect Level,” or NOAEL) by some “uncertainty” factor.15 Usually 
the factor is 100 or 1000, although the choice of what uncertainty 
factor to use is dictated by the nature of the toxic response, the 
quality and quantity of the experimental animal data, and the level 
of understanding of the mechanism of action of the toxic 
substance. 
Determining the causal relationship between a chemical 
exposure and a particular chronic disease requires careful 
consideration of a variety of factors, some of which may be unique 
to the particular end point in question. For example, establishing an 
association between a particular drug or chemical and a birth 
defect requires careful consideration of the exact timing of 
exposure during pregnancy. Thalidomide, responsible for 
development of thousands of limb malformation in Europe many 
decades ago, requires that exposure occur during a very specific 
period—as short as a few days—early in pregnancy.16 Exposure to 
the drug after the critical period during embryonic development 
                                                          
15 Id. at ch. 4. 
16 Joseph M. Lary, Katherine L. Daniel, J. David Erickson, Helen E. 
Roberts & Cynthia A. Moore, The Return of Thalidomide: Can Birth Defects be 
Prevented?, 21 DRUG SAFETY 161, 161-69 (1999). 
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when the limb buds are forming will not produce that particular 
birth defect, regardless of dose. Likewise, because the drug is 
relatively rapidly eliminated from the body, exposure very early in 
pregnancy—but that was stopped several days prior to the period 
of limb bud development—also would not produce the birth defect. 
Although there is great interest in understanding how 
environmental factors might contribute to chronic neurological 
diseases such as Alzheimer’s and Parkinson’s disease, there are 
relatively few examples where environmental exposures have been 
shown to contribute to these diseases. Perhaps the most notable 
example is that of a batch of synthetic heroin that was 
contaminated with a substance known as MPTP, and subsequently 
sold on the streets of San Francisco. Numerous young men (under 
the age of 30) presented with “rapid onset” symptoms essentially 
identical to Parkinson’s disease. On detailed investigation, it was 
learned that they had all used a synthetic heroin substance shown 
later to have contained MPTP.17 This substance is selectively toxic 
to certain nerve cells in the brain. These same cells, called 
“dopaminergic neurons,” are lost progressively with age in all 
people, resulting in Parkinson’s disease in some (those with a 
somewhat accelerated loss of cells). Thus, the street drug was able 
to do in weeks what normally takes a lifetime of “normal” aging. 
There is now great interest to find other environmental factors that 
might contribute to the enhanced rate of loss of dopaminergic 
neurons that seems to be the hallmark of Parkinson’s disease. One 
environmental chemical, an herbicide called “paraquat,” has a 
strong structural similarity to the active metabolite of MPTP, and 
thus there has been substantial toxicological and epidemiological 
inquiry into whether environmental or occupational exposure to 
paraquat might contribute to Parkinson’s disease. At this point in 
time, there is limited toxicological and epidemiological data 
suggestive of a link between paraquat exposure and Parkinson’s 
disease, but there remains great controversy and uncertainty over 
whether paraquat or other pesticides represents a substantial risk 
factor for Parkinson’s disease. 
                                                          
17 J. William Langston, The Etiology of Parkinson’s Disease With 
Emphasis on the MPTP Story, 47 NEUROLOGY (6 Suppl 3) 153, 153-60 (1996). 
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There is also substantial interest in how chemicals might 
modify the immune system. There are three ways by which 
chemical interactions with the immune system could be important. 
In the first, the chemical may cause direct toxicity to cells of the 
immune system, thereby interfering with normal immune 
functions. Numerous chemicals, including “dioxin,” have the 
ability to interfere with normal immune function, and at sufficient 
doses, may disrupt immune function.18 This could lead to enhanced 
susceptibility to infection, or perhaps even increased risk of cancer, 
since the immune system plays an important role in destroying pre-
cancerous and cancerous cells. Establishing whether a particular 
chemical has induced immune dysfunction in an individual, 
however, would require application of the same basic principles of 
toxicology and epidemiology as for any other type of toxic effect, 
including “dose-response” and the concept of thresholds. 
The second way in which a chemical might interact with the 
immune system is through the development of an “allergic” 
reaction to the chemical itself. This is illustrated by the common 
allergies to penicillin. Some chemicals are capable of triggering the 
immune system to develop antibodies against the chemical (or, 
more accurately, to a protein in the body that has been modified by 
the chemical), and subsequent exposures to that chemical can 
induce an allergic response. This is a major concern for many 
drugs, as allergic responses can be fatal. Once “sensitization” has 
occurred (e.g., the individual has developed antibodies to a specific 
chemical), relatively small doses of the chemical may be sufficient 
to trigger a response. Thus, people with allergic sensitization to a 
specific chemical may respond at a dose much lower than the 
“average” person, and the response will be qualitatively different 
(e.g., rather than causing liver damage at a high dose seen in most 
people, the “allergic” individual may have an asthmatic attack, or 
develop skin rashes or GI disturbances, at much lower doses). One 
of the most controversial areas in toxicology and environmental 
medicine is that related to a number of syndromes such as 
                                                          
18 Michael I. Luster, Michael F. Ackermann, Dori R. Germolec & Gary J. 
Rosenthal, Perturbations of the Immune System by Xenobiotics, 81 ENVTL. 
HEALTH PERSP. 157, 157-62 (1989). 
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“Multiple Chemical Sensitivity” (MCS), Gulf-War Syndrome, Sick 
Building Syndrome, Chronic Fatigue Syndrome, etc., for which an 
immunological basis may be involved.19 As noted by Kipen and 
Fiedler: 
Symptoms, and especially those without clear underlying 
medical explanations, account for a large percentage of 
clinical encounters. Many unexplained symptoms have 
been organized by patients and practitioners into 
syndromes such as chronic fatigue syndrome, multiple 
chemical sensitivity, sick building syndrome, Gulf War 
syndrome, and the like. All these syndromes are defined 
solely on the basis of symptoms rather than by medical 
signs. Some of the above-described conditions overlap 
strongly with explained conditions such as asthma. The 
relationship of such symptoms and syndromes to 
environmental exposure is often sharply debated, as is the 
distinction between the various syndromes.20 
Litigation in this area often pits toxicologists, epidemiologists, 
and/or environmental and occupational medicine specialists against 
another group of physicians identified as “clinical ecologists.” As 
noted by Goldstein and Henefin: 
Clinical ecologists . . . have offered opinions regarding 
multiple-chemical hypersensitivity and immune-system 
responses to chemical exposures. These physicians 
generally have a background in the field of allergy, not 
toxicology, and their theoretical approach is derived in part 
from classic concepts of allergic responses and 
immunology. This theoretical approach has often led 
clinical ecologists to find cause-and-effect relationships or 
                                                          
19 See Dalia Racciatti, Jacopo Vecchiet, Annalisa Ceccomancini, Francesco 
Ricci & Eligio Pizzigallo, Chronic Fatigue Syndrome Following a Toxic 
Exposure, 270 SCI. TOTAL ENV’T 27, 27-31 (2001); see also Roberto Patarca, 
Cytokines and Chronic Fatigue Syndrome, 933 ANNALS N.Y. ACAD. SCI. 185, 
185-200 (2001). 
20 Howard Kipen & Nancy Fiedler, Environmental Factors in Medically 
Unexplained Symptoms and Related Syndromes: The Evidence and the 
Challenge, 110 (Suppl 4) ENVTL. HEALTH PERSP. 597, 597-99 (2002). 
EATON.DOC 2/23/2004  7:22 PM 
22 JOURNAL OF LAW AND POLICY 
low-dose effects that are not generally accepted by 
toxicologists.21 
A third way that chemical exposures might involve the immune 
system involves the development of autoimmune diseases such as 
lupus, rheumatoid arthritis, and scleroderma. These are important 
and disabling diseases, yet our understanding of why the immune 
system sometimes goes awry is limited. Autoimmune diseases 
arise when the immune system begins to recognize normal tissues 
as “abnormal” and mounts an attack to destroy the tissue (similar 
to transplant rejection, where the transplanted organ is recognized 
as foreign by the immune system). Because the etiology of 
autoimmune disease is largely unknown and unpredictable, there 
have been many efforts to identify environmental factors that 
contribute to the development of autoimmune diseases. Probably 
the most extensively studied disease in this regard is lupus 
(Systemic Lupus Ereythematosus, SLE). About a half a dozen 
drugs have been definitively linked with lupus, with dozens more 
implicated.22 However, the list of non-drug “environmental” 
chemicals that have been definitively shown to cause lupus (or 
other autoimmune diseases) is much shorter. Some inorganic 
substances, in particular silica, gold, cadmium, and mercury, have 
been shown to induce autoimmunity in animals and humans. There 
is suggestive data that exposure to organic solvents, certain 
chlorinated hydrocarbons such as vinyl chloride, trichloroethylene, 
and hexachlorobenzene, can also induce autoimmunity, although 
the scientific evidence (both toxicological and epidemiological) for 
this is marginal. It remains an area of scientific interest and 
controversy. 
D.  Environment and Cancer Risk 
Claims of cancer, or increased cancer risk, or fear of cancer, 
                                                          
21 Bernard D. Goldstein & Mary Sue Henefin, Reference Guide on 
Toxicology, in FED. JUDICIAL CTR., REFERENCE MANUAL ON SCIENTIFIC 
EVIDENCE 401, 416 (2d ed. 2000). 
22 Evelyn V. Hess, Environmental Chemicals and Autoimmune Disease: 
Cause and Effect, 181-182 TOXICOLOGY 65, 65-70 (2002). 
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following chemical exposures are often key elements of toxic tort 
litigation, and thus I will devote a substantial amount of space to 
this particular form of toxic response. While it is clear that some 
chemical pollutants (potentially found in air, food, and/or water) 
have the ability to cause cancer in either or both experimental 
animals and humans, deciding whether a particular chemical 
exposure has “more probably than not” been a “substantial 
contributing factor”—or whatever the relevant burden of proof 
might be—in a particular person’s cancer (or risk of cancer, or fear 
of cancer) is a major challenge for scientists, lawyers, judges, and 
jurors. To facilitate an understanding of the scientific challenges 
that are faced in such litigation, it is perhaps useful to look at the 
“big picture” of what scientists know—and don’t know—about the 
causes of cancer. 
1. Major Causes (Risk Factors) of Cancer 
Over the last fifty or so years, a tremendous amount of 
epidemiological data has been collected on the relationship 
between a variety of “environmental factors” and the incidence of 
cancer. Studies comparing cancer risks in different populations 
with various lifestyle, genetic, cultural, dietary, and behavioral 
characteristics have led to a reasonable understanding of the major 
“risk factors” for cancer. These data are of course based on the 
incidence of cancer in large populations, and thus it is difficult to 
ascribe “individual” risk to a specific person from these data. 
Based on such analyses, it has been stated that 85-90% of all 
cancers are “environmentally-related” and thus potentially 
preventable. It should again be emphasized, however, that the term 
“environmentally-related” in this context refers to everything other 
than genetics (including smoking, diet, lifestyle, etc.) and does not 
equate directly to “environmental pollution.” 
As illustrated in Table 1, approximately 35-40% of all cancer 
deaths are attributable to tobacco products.23 While much of this is 
                                                          
23 Richard Doll & Richard Peto, The Causes of Cancer: Quantitative 
Estimates of Avoidable Risks of Cancer in the United States Today, 66 J. NAT’L 
CANCER INST. 1191, 1191-308 (1981). Most estimates are derived from the 
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lung cancer (the leading cause of cancer-related deaths in both men 
and women in most developed parts of the world), smoking also 
increases risk of oral, bladder, kidney, and several other cancers. 
TABLE 1—“BEST ESTIMATES” OF THE MAJOR RISK FACTORS FOR CANCER 
The next most important factor—roughly equal in importance 
to smoking—is “diet.” What it is about diet that is so important 
remains uncertain. What is clear is that there are many aspects of 
the diet that can either increase or decrease cancer risk. For 
example, diets high in fruits and vegetables have consistently been 
shown to lower the risk of a variety of cancers.24 In some studies, 
                                                          
seminal work of Sir Richard Doll. Id. Recognition of infectious agents as a 
substantial contributor to several types of cancer, especially for cervical and 
stomach cancer, became evident in the past decade. Id. The American Cancer 
Society also discusses the major causes of cancer in their book, entitled: 
CANCER: WHAT CAUSES IT, WHAT DOESN’T (2003), available for purchase at 
http://www.cancer.org. 
24 See John D. Potter, Diet and Cancer: Possible Explanations for the 
Higher Risk of Cancer in the Poor, 138 INT’L AGENCY FOR RES. ON CANCER 
SCI. PUBLICATIONS 265, 265-83 (1997); Eli Riboli & Teresa Norat, 
Epidemiologic Evidence of the Protective Effect of Fruit and Vegetables on 
Cancer Risk, 78 (3 Suppl) AM. J. CLINICAL NUTRITION 559S, 559S-569S (2003); 
Antonia Trichopoulou, Androniki Naska, Antonis Antoniou, Sharon Friel, Ku 
Trygg & Alessandro Turrini, Vegetable and Fruit: The Evidence in Their 
Favour and the Public Health Perspective, 73 INT’L J. FOR VITAMIN NUTRITION 
Factors                                          Best Estimate (%)                 Range (%)     
Tobacco     35               25 – 40 
Diet     35               10 – 70 
Cultural and Lifestyle factors     10                   1 – 13 
Infectious agents     10                   5 – 20 
Genetics      5                   2 – 10 
Occupation      4                    2 – 8 
Alcohol      3                    2 – 4 
Geophysical factors (e.g., radon)      3                    2 – 4 
Medicines/medical procedures      1               <1 – 3 
Pollution      2                                <1 – 5 
Industrial Products    <1                                <1 – 2 
Food additives    <1                                - 5 – 2 
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diets high in animal fat have been associated with increased risk of 
some common cancers (e.g., breast), but the relationship is not 
always seen, and it remains unclear whether the amount and/or 
type of fat in the diet are important risk factors. There are also 
some chemical contaminants in the diet that may increase cancer 
risk, but again for most populations it is not clear how important 
natural dietary carcinogens (cancer-causing chemicals) are to 
overall cancer risk. In some parts of the world, however, a 
common mold contaminant of corn and peanuts—called 
“aflatoxin”—is certainly an important contributor to the very high 
incidence of liver cancer. It has been shown that aflatoxin is much 
more dangerous in populations where hepatitis B viral infections 
are common.25 
The third most important category of risk factors revolves 
around cultural and lifestyle factors, which includes sexual 
practices and reproductive factors. Often these cultural factors 
interact with other environmental factors, such as viruses. For 
example, it is now recognized that almost all cervical cancer is due 
to infection with the human papilloma virus (HPV), which is 
transmitted through sexual activity. For reasons that are unclear, 
cervical tissue in teenage women seems more susceptible to HPV 
infection than that in older women. Thus, sexual activity at a 
young age is a major risk factor for cervical cancer. While this 
disease is relatively easily diagnosed (via Pap smear) and treated if 
detected early, large differences in access to medical care and sex 
education can make a huge difference in the mortality of this 
disease across populations. 
Breast cancer is the second leading cause of cancer-related 
deaths among women in the United States and many other 
developed countries, trailing only smoking-related lung cancer. 
The major risk factor for breast cancer appears to be a constellation 
of reproductive factors that influence a woman’s “lifetime dose” of 
unopposed estrogen. Thus, the age of onset of menstruation, the 
                                                          
RES. 63, 63-69 (2003). 
25 Thomas W. Kensler, Gang-Sun Qian, Jiang-Guo Chen & John D. 
Groopman, Translational Strategies for Cancer Prevention in Liver, 3 NATURE 
REV. CANCER 321, 321-29 (2003). 
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age of onset of menopause, the number of children, the age of first 
pregnancy, and the extent of breast-feeding, all influence breast 
cancer risk. Thus, it is not surprising that breast cancer incidence 
and mortality is much lower in countries and cultures where 
women have their first children early in life, have multiple 
children, breast feed for extended periods, and often have dietary 
habits that postpone (or, at least don’t accelerate) the onset of 
menstruation, compared to a typical “suburban U.S.” lifestyle. 
Recently, there has been much public press coverage of the 
discovery of several “breast cancer genes” (BRCA1, BRCA2, 
BRCA3).26 Although there is little question that women who carry 
variant forms of the genes are at substantially increased risk of 
developing breast cancer (especially at a younger age), the overall 
contribution of these rather rare genetic causes of breast cancer is 
probably substantially less than 10% of all breast cancers. Thus, 
the large majority of breast cancers seem not to have major genetic 
contributors. But it remains uncertain whether there are important 
“environmental susceptibility” genes that might interact with 
environmental factor(s) to substantially increase breast cancer risk. 
Of the various identifiable “environmental” factors not 
associated with diet or lifestyle, infectious agents seem to play a 
more important role than was expected only a decade ago. It is 
now clear that well over 90% of cervical cancers are due to HPV 
infections.27 Many cases of stomach cancer are directly attributable 
to a chronic bacterial infection from helicobacter coli.28 Most cases 
                                                          
26 See Peg Brickley, Repairing BRCA1 Science DNA-Repair Researchers 
Trying to Separate Sound Science from Allegedly False Data in Retracted 
Papers, THE SCIENTIST, June 18, 2003; Jeffrey Krasner, Marketing of Cancer-
Gene Test Raises Ethical Medical Concerns: Gene Test Ads Prompt Concern, 
BOST. GLOBE, Mar. 26, 2003, at D1; Rick Weiss, 2 Genes Make Cancer Risk 
Soar; Women’s Odds Not Tied to Family Health, Study Finds, WASH. POST, Oct. 
24, 2003, at A1. 
27 See F. Xavier Bosch & Silvia de Sanjose, Human Papillomavirus and 
Cervical Cancer—Burden and Assessment of Causality, 31 J. NAT’L CANCER 
INST. MONOGRAPHS 3, 3-13 (2003); Steven E. Waggoner, Cervical Cancer, 361 
LANCET 2217, 2217-25 (2003). 
28 Jon R. Kelley & John M. Duggan, Gastric Cancer Epidemiology and 
Risk Factors, 56 J. CLINICAL EPIDEMIOLOGY 1, 1-9 (2003). 
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of liver cancer worldwide can be attributable to hepatitis B (and 
probably C) viral infections, and alcohol consumption.29 Even the 
HIV virus responsible for AIDS is associated with substantially 
increased risk for certain types of cancer.30 It is possible, although 
still not proven, that a significant fraction of human blood-related 
cancers (leukemias and lymphomas) have a viral etiology, as 
several leukemia viruses have been identified in animals. 
What role do “man-made” chemical pollutants, such as heavy 
metals, pesticides, industrial solvents, asbestos, etc., play in overall 
cancer risk? As indicated in Table 1, “occupation” is thought to be 
responsible for 3-5% of all cancers, although there is reasonable 
hope and expectation that this will decline substantially as the long 
history of high-level occupational exposures to cancer-causing 
substances becomes a relic of the past.31 But the incidence of 
asbestos-related lung cancer and mesothelioma, derived from 
occupational exposures that occurred predominantly in the ’40s, 
’50s, ’60s and early ’70s has not yet peaked, since latency period 
(time from first exposure to the development of clinical disease) 
may be as long as fifty to sixty years in some individuals. Greatly 
improved awareness and early identification of potential cancer-
causing chemicals, coupled with significant improvements in 
workplace controls, monitoring, and worker education (at least in 
developed countries) should result in a drastic reduction in the 
incidence of occupationally related cancers in the future. 
Probably the most uncertain and controversial contributor to 
cancer risk is that associated with environmental pollution.32 
                                                          
29 Renuka Bhattacharya & Margaret C. Shuhart, Hepatitis C and Alcohol: 
Interactions, Outcomes, and Implications, 36 J. CLINICAL GASTROENTEROLOGY 
242, 242-52 (2003); Timothy M. Block, Anand  S. Mehta, Claus J. Fimmel & 
Robert Jordan, Molecular Viral Oncology of Hepatocellular Carcinoma, 22 
ONCOGENEOLOGY 5093, 5093-107 (2003). 
30 Eliabeth Y. Chiao & Susan E. Krown, Update on Non-acquired 
Immunodeficiency Syndrome-Defining Malignancies, 15 CURRENT OPINIONS 
ONCOLOGY 389, 389-97 (2003). 
31 See supra note 23 & Tbl. 1. 
32 See Julia G. Brody & Riuthann A. Rudel, Environmental Pollutants and 
Breast Cancer, 111 ENVTL. HEALTH PERSP. 1007, 1007-19 (2003); Shuanfang 
Li, Stephen D. Hursting, Barbara J. Davis, John A. McLachlan & J. Carl Barrett, 
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Although it is very difficult to make reasonable “estimates” of the 
contribution of environmental pollution to overall cancer incidence 
and mortality, most experts place the number at only a few percent, 
at most. However, even 1% of 500,000 deaths a year is not an 
insignificant number (5000) of potentially preventable deaths, so 
efforts to reduce the use and release of chemical carcinogens are 
not ill-founded. The challenge comes in balancing the potentially 
real, but very low, risks of cancer in a large population against the 
societal benefits that come from the industrial and consumer 
activities that contribute to the pollution. The basic ways that 
chemicals can increase cancer risk (chemical carcinogenesis) and 
the process of “carcinogenic risk assessment” for chemical 
pollutants are discussed in more detail below. 
One example in the area of environmental carcinogenesis that 
has been the subject of substantial tort and regulatory litigation is 
that of “dioxins.”33 Dioxins represent a group of industrial by-
products produced inadvertently in the chemical manufacture of 
trichlorophenol (TCP). TCP was widely used in the synthesis of 
the herbicide, 2,4,5 trichlorophenoxy acetic acid (2,4,5-T), a 
component of Agent Orange. TCP was also used in the 
manufacture of the antibacterial soap ingredient, hexachlorophene, 
so many antibacterial soaps were also contaminated with trace 
amounts of dioxins. Although there are more than a dozen specific 
“dioxin” chemicals, the term is generally used to refer to one 
                                                          
Environmental Exposure, DNA Methylation, and Gene Regulation: Lessons 
from Diethylstilbesterol-Induced Cancers, 983 ANNALS N.Y. ACAD. SCI. 161, 
161-69 (2003); William G. Thilly, Have Environmental Mutagens Caused 
Oncomutations in People?, 34 NAT’L GENETICS 255, 255-59 (2003). 
33 See Andrew Blum, Dioxin Cases: Lengths and Results Vary, 10 NAT’L 
L.J. 3 (1988); Richard Pliskin, Dioxin Case Ends with a Whimper: Ironbound 
Health Rights Advisory Commission v. Diamond Shamrock Chemicals Co., 130 
N.J.L.J. 1 (1992); Verdict in One of Nation’s Longest Trials Reached a Year 
Ago Saturday (Kemner v. Monsanto), 134 CHIC. DAILY L. BULL. 1 (1988); John 
Deakle & Nicholas Varchaver, Muddy Waters; Georgia-Pacific is Mired in 
Mississippi, Facing 8,800 Plaintiffs and Billions of Dollars in Potential 
Liability, Thanks to Dioxin-Emitting Paper Mill and a Local Plaintiffs Lawyer 
Who Won’t Go Away, 15 AM. LAW. 52 (1993); William Boyd, Controlling Toxic 
Harms: The Struggle Over Dioxin Contamination in the Pulp and Paper 
Industry, 21 STAN. ENVTL. L.J. 345 (2002). 
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highly toxic form, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). 
When tested in experimental animals, TCDD is extremely toxic, 
causes cancer and birth defects at extraordinarily low doses, and is 
generally considered the most toxic and carcinogenic man-made 
chemical ever studied. Dioxins represent an interesting challenge 
to the courts for several reasons. First, there are very large species 
differences in susceptibility to the toxic—and presumably 
carcinogenic—effects of TCDD. For example, the single lethal 
dose of dioxin in guinea pigs is approximately 0.1 micrograms per 
kg of body weight, whereas the lethal dose in hamsters is more 
than 10,000 times greater. Second, although studies in rats and 
mice provide consistent evidence that “dioxin” is a potent and 
effective carcinogen, human epidemiology studies are less 
convincing. Furthermore, dioxin is not appreciably metabolized in 
the body, nor does not cause mutations, and the “mechanism” by 
which it causes cancer is uncertain. Because it is very soluble in fat 
and is not metabolized in the body, it remains in the body for many 
years following exposure. Because potentially tens of thousands of 
military personnel were exposed to dioxin during the Vietnam 
War, and because of the widespread use of certain herbicides 
containing small amounts of dioxins in agriculture, forest practices, 
utility and highway right of ways, and even residential property, it 
has been the subject of extensive toxic tort litigation.34 Although it 
is probably one of the most extensively studied chemical 
carcinogens, there remains substantial scientific uncertainty as to 
the actual levels of cancer risk to humans exposed to trace levels of 
dioxins in the environment. 
2.  General Mechanisms of Chemical Carcinogenesis 
Chemicals that cause an increased incidence of cancer in a 
population (experimental animals or humans) following exposure 
are referred to as “carcinogens.”35 The process of chemical 
carcinogenesis is “multi-stage,” such that several events must 
                                                          
34 See sources cited supra note 33. 
35 CASARETT AND DOULL’S TOXICOLOGY: THE BASIC SCIENCE OF POISONS, 
supra note 11, at Ch. 8. 
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occur before a normal cell is transformed into a malignant (cancer) 
cell. Typically, the process of carcinogenesis is divided into four 
general stages: (1) initiation, (2) promotion, (3) progression and (4) 
metastasis. A chemical carcinogen may increase the incidence of 
tumors by acting at any or all of these various stages. One of the 
most important ways that a chemical may act as a carcinogen is by 
interacting with DNA in somatic cells to cause mutations. (Somatic 
cells refer to all cells in the body except sperm and egg cells 
(ova)). Mutations in somatic cells may lead to permanent changes 
in the DNA that result in critical changes in the way the cell 
controls its rate of cell division. Such a permanent alteration in 
DNA of a somatic cell is referred to as “initiation,” and represents 
the first stage of chemical carcinogenesis. Because initiation 
results in a permanent change in the DNA of a cell that is 
subsequently passed on to all “daughter” cells following division 
of the mutated cells, initiation is generally considered to be an 
irreversible process, and initiated cells may accumulate in the body 
throughout life. 
By definition, all chemicals that are “initiators” are mutagenic, 
and thus short-term tests that demonstrate the mutagenic ability of 
a chemical make it a suspect carcinogen.36 However, not all 
chemicals that test positive in mutagenicity assays are carcinogenic 
for a variety of reasons. Nevertheless, a chemical that consistently 
tests positive in numerous different short-term mutagenicity assays 
is more likely to be carcinogenic than a chemical that routinely 
tests negative. However, as with all toxicological responses, the 
“dose-response” for mutagenesis is critically important to consider. 
Thus, when considering the potential health significance of 
exposure to chemical mutagens that may act as carcinogens, it is 
important to keep the total or cumulative “dose” in mind, as the 
critical issue is whether there is a biologically relevant increase in 
the “background” rate of DNA damage from all other sources over 
the lifetime of an individual. 
Although initiation is an essential first step toward cancer, most 
initiated cells do not go on to become cancers because they usually 
require additional genetic changes and other external stimuli to 
                                                          
36 Id. 
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become true cancer cells. An initiated cell is analogous to a car 
whose accelerator is stuck part way on. As long as the brakes 
work, the speed and control of the car can be adequately 
maintained. However, if a second change occurs, resulting in the 
loss of the brakes, then the car can no longer be controlled. It 
should be recognized that the vast majority of mutations in a cell 
do not have any effect on cell growth and regulation, just as most 
mechanical malfunctions in a car do not result in a stuck 
accelerator or loss of brakes. 
The second step of carcinogenesis, referred to as “promotion,” 
occurs when some external stimuli, including exposure to certain 
chemicals, increases the rate of cell proliferation of initiated cells 
or otherwise enhances the ability of an initiated cell to become 
cancerous, but does not directly interact with DNA. A chemical 
that increases cancer risk by acting as a promoter of carcinogenesis 
is generally considered to be less of a concern because the 
promoting stimulus goes away when the exposure stops—e.g., 
promotion is “reversible.” The process of promotion can be viewed 
as a relatively early stage in carcinogenesis where an initiated cell 
is stimulated to divide repeatedly to give rise to a small colony of 
initiated cells (a “preneoplastic” lesion). 
The third stage of carcinogenesis, referred to as progression, 
represents the long period of time where the small colony of 
initiated cells acquires additional mutations that further transform 
the cell from a normal cell to a cancer cell. To return to the car 
analogy, additional mutations damage the cell’s “brakes,” 
“steering,” or other critical functions necessary to properly 
maintain control. 
The probability of a single cell acquiring all of the necessary 
genetic changes to convert it from a normal cell to a cancer cell 
depends on a variety of factors, including the dose and duration of 
exposure to mutagenic substances. Exposure to man-made 
mutagenic chemicals can increase cancer risk. However, it should 
be recognized that the vast majority of DNA damage that occurs in 
our cells results from normal metabolic processes and exposure to 
natural components in the diet or to UV radiation in sunlight. As a 
cell “burns” sugars to produce energy it generates reactive by-
products of oxygen. These by-products, called “free radicals” or 
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“reactive oxygen species” (ROS) can and do directly damage 
DNA. In addition, common chemicals found naturally in the diet 
and/or formed during cooking can also damage DNA (e.g., act as 
mutagens). Fortunately, the cells of the body have remarkable 
processes that can reduce the damage to DNA from ROS and 
mutagenic chemicals (both natural and man-made), as well as 
repair damaged DNA. Many vitamins and certain chemicals found 
naturally in the diet (especially in fruits and vegetables) act as 
“antioxidants” and can help protect cells from the DNA damaging 
effects of ROS and chemicals (both man-made and natural) that 
damage DNA. This is one reason why diet is so important in 
lifetime cancer risk. Many studies have demonstrated that diets 
high in fruits and vegetables lower the risk of many types of 
cancer.37 
Because the probability of a single somatic cell acquiring all of 
the necessary genetic changes (mutations) to become a cancer cell 
is quite small and is a function of the period of time that a cell has 
to acquire such mutations, cancers that occur because of exposure 
to a carcinogen are both relatively rare in an exposed population 
and are usually not seen until many years after the initial period of 
exposure. For cancers caused by prolonged or repeated exposure to 
a chemical, the time frame from first exposure to when the disease 
becomes clinically evident is referred to as the “latency” period. In 
general, the latency period is somewhat inversely related to the 
extent of exposure (dose). For most human cancers that are related 
to chemical carcinogen exposure (e.g., cancers related to cigarette 
smoking), the latency period is usually twenty to forty years. 
Certain cancers (mesotheliomas) that arise from occupational 
exposure to asbestos typically are not seen for thirty or more years 
after first exposure.38 The shortest latency period possible appears 
to be at least a couple of years following very high levels of 
exposure to mutagenic chemicals used to treat cancers, especially 
leukemias.39 Because latency seems to be inversely related to dose, 
                                                          
37 See sources cited supra note 24. 
38 Mark Britton, The Epidemiology of Mesothelioma, 29 SEMINARS 
ONCOLOGY 18, 18-25 (2002). 
39 Richard A. Larson, Michelle M. LeBeau, James W. Vardiman & Janet D. 
EATON.DOC 2/23/2004  7:22 PM 
 TOXICOLOGY IN LITIGATION 33 
very low levels of exposure to mutagenic chemicals may be of 
little practical consequence to an individual because (1) the extent 
of DNA damage is very small, relative to the “background” rate 
that occurs from all other sources, and (2) the latency period for 
developing a cancer is very long and may exceed normal life 
expectancy. Although these are very important practical biological 
considerations, they are often not considered in quantitative risk 
assessment of low dose carcinogen exposures by regulatory 
agencies, who usually assume that risk is directly proportional to 
dose at low doses (the “linearized dose-response” approach to 
cancer risk assessment). 
Another factor that affects the occurrence of a cancerous cell is 
the rate of cell turnover, or “cell proliferation.”40 Because all cells 
have a background incidence of spontaneous mutations, the 
likelihood of a cell becoming mutated is related to the rate of cell 
replication, analogous to rolling dice. The more often the dice are 
rolled the more likely a specific number is to appear. This factor is 
especially important in considering the use of high doses of 
chemicals in laboratory animal test for cancer-causing potential. 
When doses of the test chemical are so high that they cause tissue 
damage (and thus stimulate cell division to repair the damage)—
which usually would not occur at low doses—direct extrapolation 
of the rate of tumor formation in the animals given high doses to 
humans exposed to much lower doses that don’t cause tissue 
damage is of questionable scientific value.41 The particular rodent 
strains used also often have a high background rate of spontaneous 
tumors.42 Thus, any chemical that damages cells and causes 
considerable regeneration (i.e., cell proliferation) may increase the 
                                                          
Rowley, Myeloid Leukemia After Hematotoxins, 104 (Suppl 6) ENVTL. HEALTH 
PERSP. 1303, 1303-07 (1996). 
40 Samuel M. Cohen, Cell Proliferation and Carcinogenesis, 30 DRUG 
METABOLISM REV. 339, 339-57 (1998). 
41 Samuel M. Cohen, Urinary Bladder Carcinogenesis, 26 TOXICOLOGY 
PATHOLOGY 121, 121-27 (1998); Lois S. Gold, Thomas H. Slone & Bruce N. 
Ames, What Do Animal Cancer Tests Tell Us About Human Cancer Risk? 
Overview of Analysis of the Carcinogenic Potency Database, 30 DRUG 
METABOLISM REV. 359, 359-404 (1998). 
42 See Gold, supra note 41; see also Zito, supra note 13. 
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likelihood of a cancerous cell occurring. 
E.  Use of Toxicological Data to Assess Chemical Risks in 
Populations and Individuals 
It is important to recognize that the procedures commonly used 
in “risk assessment” for the purposes of establishing public health 
guidelines that represent “acceptable” exposure levels for large 
populations are often, in this author’s opinion, of marginal 
relevance to estimating “causation” in an individual—e.g., whether 
a particular chemical caused or contributed to a particular disease 
or illness in a given person. Although toxicological data—and the 
basic principles of toxicology outlined above—are useful for both 
(establishing guidelines for protection of public health and 
establishing “causation”), there are substantial differences in 
approach. Thus, use of toxicological data for these two distinct 
purposes will be discussed separately in the following sections. 
F.  Use of Toxicological Data to Establish “Acceptable” 
Levels of Exposure for Large Populations (Public 
Health) 
Much of the available dose-response criteria for assessing 
chemical toxicity and risks to human health are based on protective 
guidelines developed by federal (e.g., EPA, ATSDR) and 
sometimes state agencies. The federal government and national 
organizations using similar approaches also set occupational health 
guidelines and standards for protection of workers. Guidelines for 
protection of the general public are usually more stringent than for 
workers, who are assumed to be part of a healthier and less 
sensitive population. Public health guidelines, however, should not 
be interpreted as predicting exact levels at which effects would 
occur in a given individual. Because a number of protective, often 
“worst-case” assumptions (e.g., exposure to any dose of a 
carcinogenic chemical based on animal studies confers a risk of 
cancer in humans, high daily exposure for a lifetime) are made in 
estimating allowable exposures for large populations, these criteria 
and the resulting regulatory levels (e.g., MCLGs, MCLs) generally 
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overestimate potential toxicity levels for nearly all individuals. 
Furthermore, because these guidelines are intended to be protective 
of all individuals in a population, including the very young, the 
very old, and other potentially “sensitive” individuals, the 
theoretical risks from exposure at the guideline level is likely to be 
substantially overestimated for the large majority of individuals in 
the population. Nevertheless, they can provide useful guidance to 
public health agencies that have the responsibility of protecting all 
individuals in large populations. 
Public Health criteria developed by the EPA for individual 
chemicals usually include determination of non-cancer reference 
doses and “cancer potency” or “slope factors.” Non-cancer 
reference doses represent the dose below which no adverse health 
effects are expected, even in sensitive individuals exposed 
repeatedly at the defined level for many years. Reference doses are 
usually derived from “No Observable Adverse Effect Levels” 
(NOAELs) or “Lowest Observable Adverse Effect Levels” 
(LOAELs) in the toxicological literature. NOAELs and LOAELs 
are usually determined from experimental animal studies, rather 
than human exposures. The term “Reference Dose” is frequently 
used to refer to a dose of a chemical to humans that could be 
consumed on a daily basis for a lifetime with no chance of anyone 
exhibiting an adverse response (the specific definition of such 
“safe” doses varies from agency to agency and regulation to 
regulation). Reference Doses are obtained by dividing the 
“NOAEL” dose determined in animal studies by an Uncertainty 
Factor. Uncertainty Factors usually range from 100 to 1000, 
depending on the amount of uncertainty in, for example, 
extrapolating from animals to humans, short-term to long-term 
effects, average to sensitive members of the population.43 
Generally, the more uncertainty factors required, the more likely it 
is that the Reference Dose will be lower than what would actually 
be necessary for protection of humans because each uncertainty 
factor errs on the side of overprotection. Thus, although health 
authorities can confidently expect that exposures below reference 
dose levels will not result in adverse effects, the converse is not 
                                                          
43 See sources cited supra notes 13 & 14. 
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true. Exposures in a given individual that exceed a reference dose 
level do not signify that effects are likely to occur because of the 
margin of “safety” built into these Reference Doses which are 
intended to provide guidance for protecting even sensitive 
members of the population. Thus, such regulatory levels are of 
substantial value to public health agencies charged with ensuring 
the protection of the public health, but are of limited value in 
judging whether a particular exposure was a substantial 
contributing factor to a particular individual’s disease or illness. 
G.  Determining Regulatory Guidelines for Chemical 
Carcinogens for Protection of Public Health 
For carcinogens, most regulatory agencies have used “default” 
assumptions about the dose-response relationship such that it is 
assumed that the risk of developing cancer is proportionate to dose 
at all doses (e.g., there is no “threshold” dose).44 Thus, to establish 
socially acceptable levels of exposure to carcinogens commonly 
found in food, air and water, the EPA, FDA, and other regulatory 
agencies have established guidelines for conducting risk 
assessments.45 Using such procedures, “acceptable,” “tolerable,” 
“permissible,” or “safe” levels of exposure to a specific chemical 
are often established based on regulatory policy decisions on 
allowable risk, or tradeoffs between risk reduction and cost.46 For 
contaminants in drinking water, such levels are referred to as 
“Maximum Contaminant Levels,” or MCLs. The EPA has a long-
standing policy that dictates that the desired level of cancer risk for 
a contaminant in drinking water is zero.47 Thus, for carcinogens the 
EPA has established MCLGs (Maximum Contaminant Level 
Goals) of zero. However, because zero levels are generally not 
                                                          
44 See ENVTL. PROT. AGENCY, EPA 630/P-03/001A, NCEAA-F-0644A, 
DRAFT FINAL GUIDELINES FOR CARCINOGEN RISK ASSESSMENT (2003). Earlier 
adopted versions also have assumed linearity at low dose. Id. 
45 See id.; Zito, supra note 13. 
46 See ENVTL. PROT. AGENCY, supra note 44. 
47 See U.S. Envtl. Prot. Agency, Setting Standards for Safe Drinking Water, 
at http://www.epa.gov/safewater/standard/ setting.html (last modified Aug. 7, 
2003). 
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achievable by modern technology, the actual drinking water 
standards, MCLs, are usually based on other considerations such as 
technical feasibility, cost-benefit analysis, and background levels. 
However, even if the standard is based primarily on a technology 
or cost, MCLs for most such chemicals in drinking water must still 
be within an acceptable range of health risk. For cancer risk from 
chemicals in drinking water, the EPA has stated this range to be an 
excess lifetime risk of cancer over background of one in 1,000,000 
to one in 10,000. However, there are some exceptions where 
MCLs have been established that yield theoretical excess lifetime 
cancer risks much greater than one in 10,000. The recent adoption 
of an MCL for arsenic in drinking water of 10 ppb is such an 
example.48 
Because the lifetime probability of dying from cancer for 
someone living in the United States is about 1 in 4 (25%, or 0.25 
lifetime probability), a theoretical increase in lifetime cancer risk 
(mortality) of 1 in 100,000 would provide a potential increase in 
overall lifetime probability of dying from cancer from 
approximately 0.25 to approximately 0.25001. Thus, when citizens 
are confronted with evidence that their drinking water is 
contaminated with a “cancer causing chemical” at levels that 
exceed federal regulatory limits, it becomes important to ensure 
that the public understands how such standards are derived and the 
significance of the potential increase in risk, relative to other 
common risks encountered daily. 
EPA cancer “slope factors” represent the slope of the dose-
response relationship statistically extrapolated from studies of high 
dose exposure and cancer in laboratory animals or human 
populations. The EPA default assumption in these slope factors is 
that no dose of a carcinogenic chemical is without some risk of 
cancer and that one can extrapolate high dose exposures and the 
risk of cancer to low doses. The use of a slope factor in this 
                                                          
48 See U.S. Envtl. Prot. Agency, Arsenic in Drinking Water, at 
http://www.epa.gov/safewater/arsenic.html (last modified July 14, 2003); 
SUBCOMMITTEE TO UPDATE THE 1999 ARSENIC IN DRINKING WATER REPORT, 
NAT’L RES. COUNCIL, ARSENIC IN DRINKING WATER: 2001 UPDATE (2001), 
available at http://www.nap.edu/catalog/10194.html (last visited Dec. 5, 2003). 
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manner ignores the ample evidence that for many carcinogenic 
chemicals, practical thresholds may exist for significant cancer risk 
because of detoxification mechanisms at low doses (e.g., 
difference in metabolism of the chemicals at high dose versus 
lower doses) or because of the mechanisms of action. Therefore, 
these slope factors cannot be expected to accurately predict a risk 
of cancer, if any, in a given individual at low doses. Although they 
may be somewhat useful to make crude estimates of individual 
risk, many assumptions go into the determination of the cancer 
slope factor, and it is important to consider the relevance of the 
particular animal study from which the slope factor was 
determined when attempting to use such values in individual risk 
calculations. 
H.  Use of Toxicological Data in Assessment of Individual 
Causation 
When assessing whether a particular potentially toxic 
substance is a substantial contributing factor to an individual’s 
disease or illness, the “regulatory approach” is of little value, 
although much of the same toxicological and epidemiological data 
may be used in evaluating causation. The key scientific criteria 
used to establish causation between an alleged chemical exposure 
and a particular disease or illness includes the following basic 
concepts: 
1. The toxic substance in question must have been 
demonstrated to cause the type of illness or disease in question. 
This addresses the issue of general causation as well as specific 
causation, and may be demonstrated either in humans following 
known exposures (usually from accidents, occupational exposures, 
or intentional exposures), or, in the absence of human data, in 
experimental animals intentionally exposed to the agent in 
question. Because most chemicals that are widely encountered in 
the environment, such as pesticides, metals, and industrial solvents, 
are manufactured, workplace exposure to humans may occur. 
Occupational health and safety regulations require workplace 
monitoring, and thus there is frequently a substantial amount of 
toxicologically relevant data from workplace monitoring that can 
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be used to assess whether a particular chemical is capable of 
causing a particular disease or illness. Indeed, virtually all 
synthetic chemicals identified by EPA or International Agency for 
Research on Cancer as “known human carcinogens” have been 
identified as such through studies of workers exposed to the 
chemical in the workplace. Workplace exposures are typically 
hundreds to thousands of times greater than incidental 
environmental exposures that might occur from contamination of 
drinking water, or off-site migration of chemicals via the air. 
2.  The individual must have been exposed to a sufficient 
amount of the substance in question to elicit the health effect in 
question. As noted above, the main tenant of toxicology is the 
“dose-response” relationship. If criterion (1) above has been 
established for a given chemical, then it must be established that 
the individual’s dose over a defined period of time was sufficient 
to cause the alleged health effect. It is not adequate to simply 
establish that “some” exposure occurred. Because most chemically 
induced adverse health effects clearly demonstrate “thresholds,” 
there must be reasonable evidence that the exposure was of 
sufficient magnitude to exceed the threshold before a likelihood of 
“causation” can be inferred. For carcinogenic chemicals that act 
via mutagenic action, a threshold may not be evident. Thus, 
although any level of exposure will theoretically increase the 
probability of developing the disease, the risk follows a dose-
response relationship, and the dose must be sufficient to 
“significantly” elevate the risk above the background. What 
represents a “significant” increase in cancer risk is of course 
subjective and influenced by many factors. However, as noted 
above, because the process of chemical carcinogenesis is always 
associated with a “latency,” and the latency period is generally 
inversely related to dose, at very low doses of even “direct acting,” 
mutagenic carcinogens, the latency period might exceed life 
expectancy, thereby imparting a “practical” threshold. 
3. The chronological relationship between exposure and effect 
must be biologically plausible. If a disease or illness in an 
individual preceded the established period of exposure, then it 
cannot be concluded that the chemical caused the disease, although 
it may be possible to establish that the chemical aggravated a pre-
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existing condition or disease. For cancer cases, diagnosis of the 
cancer in a time frame close to the beginning period of exposure 
(i.e., within a few years) argues strongly against a causal 
relationship, since, as noted above, chemically-induced cancers 
have latency periods that are nearly always in excess of five years, 
and are somewhat inversely related to dose. 
4. The likelihood that the chemical caused the disease or 
illness in an individual should be considered in the context of other 
known causes.  Although this consideration may not be essential to 
establish general causation, it is a critical consideration in the 
quantitative assessment of whether the substance was “more likely 
than not” a cause or substantial contributing factor to the disease or 
illness in a specific person. This is especially important in cancer 
causation, because cancer is by its very nature a multi-factorial 
disease. As discussed above, chemicals that are mutagenic have the 
theoretical potential to increase cancer risk even at very low doses, 
although there is a point at which the theoretical risk is trivial, 
relative to all other causes, known and unknown. As there are 
literally hundreds, if not thousands, of mutagenic naturally-
occurring chemicals present at low levels in our diet and thus also 
present theoretical cancer risks, it becomes important to put such 
theoretical, “low dose” risks in perspective.49 
J.  Multiple Exposures/Mixtures 
Another area of relevance to human risk assessment for 
environmental pollutants is the fact that, unlike experimental 
animals, humans may be exposed to multiple different chemicals, 
diets, and lifestyle factors that affect the dose-response relationship 
for a given chemical. For chemical carcinogens, it is often assumed 
that the risks are additive even though they may not act through 
similar mechanistic pathways. That is, the risk for each chemical in 
a mixture is calculated separately, and the total risk from exposure 
to the mixture is simply the sum of the risks for each individual 
chemical. While there are examples of non-additive responses 
(both “synergistic,” where the response of two chemicals is greater 
                                                          
49 See Kipen & Fiedler, supra note 20. 
EATON.DOC 2/23/2004  7:22 PM 
 TOXICOLOGY IN LITIGATION 41 
than predicted from adding the individual response alone, and 
“antagonistic,” where one chemical appears to reduce the risk of 
the second), unless there is compelling evidence to the contrary, 
additivity of risks for all carcinogens is generally assumed. 
However, for carcinogens that act via different modes (e.g., 
genotoxic vs. non-genotoxic carcinogens), additivity is less certain, 
and mechanistic data may warrant consideration of non-additive 
models for interaction. 
EPA risk assessment guidelines also consider non-cancer 
effects of chemicals to be additive, particularly if they effect the 
same endpoint at lower doses. If the chemicals act by the same 
mechanism, then their action could be additive even when 
exposure to each is below a dose that would cause effects. 
III.  FUTURE SCIENTIFIC OPPORTUNITIES AND CHALLENGES IN 
TOXIC TORT LITIGATION 
The past decade has seen a tremendous advance in DNA-based 
technologies that offer exciting challenges and opportunities to the 
field of toxicology. The growing area of “toxicogenomics”—the 
application of new molecular technologies to understand how 
chemicals cause adverse responses in cells, tissues, and 
organisms—will eventually play an important role in toxic tort 
litigation. Rather than examining the effect of a chemical on one or 
a few biochemical pathways, the tools of toxicogenomics provide a 
means to examine the global response of a cell to a chemical 
stimulus, resulting potentially in a “fingerprint” alteration in 
expression of thousands of different genes (transcriptomics), 
proteins (proteomics), or cellular metabolites (metabonomics). The 
potential exists for such tools to provide convincing proof that a 
particular disease was related to a specific chemical exposure, 
through unique changes that potentially can be measured years 
after the exposure occurred. As noted by Marchant, however, 
“many obstacles and uncertainties remain to be resolved before 
toxicogenomics data should be used outside the research context 
for practical, regulatory or legal applications.”50 Until such time as 
                                                          
50 See Marchant, supra note 6; see also John C. Childs, Toxicogenomics: 
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these new scientific approaches to linking specific diseases or 
illnesses to specific exposures can be proven reliable, judges, 
lawyers, and jurors must rely upon the basic scientific principles of 
toxicology and epidemiology to establish causation in toxic torts. 
 
                                                          
New Chapter in Causation and Exposure in Toxic Tort Litigation, 69 DEF. 
COUNCIL J. 441, 441-46 (2002). 
